It has been reported that apatinib, a specific VEGFR-2 inhibitor, temporarily promotes tumor vascular normalization by blocking the transmission of the VEGF/VEGFR-2 signaling pathway and improves pemetrexed therapy. Here, KDR is linked to neoplasm.